TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

@article{Dreger2013TP53SA,
  title={TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.},
  author={Peter Dreger and Andrea Schnaiter and Thorsten Zenz and Sebastian Boettcher and Marianna Nicoletta Rossi and Peter Paschka and Andreas B{\"u}hler and Sascha Dietrich and Raymonde M Busch and Matthias Ritgen and Donald Bunjes and Matthias Zeis and Michael Stadler and Lutz Uharek and Christof Scheid and Ute Hegenbart and Michael J Hallek and Michael Kneba and Norbert Schmitz and Hartmut D{\"o}hner and Stephan Stilgenbauer},
  journal={Blood},
  year={2013},
  volume={121 16},
  pages={3284-8}
}
The purpose of this analysis was to provide 6-year follow-up of the CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk chronic lymphocytic leukemia (CLL), and to investigate the effect of TP53, SF3B1, and NOTCH1 mutations on HSCT outcome. For 90 allografted patients, 6-year overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%. TP53, SF3B1, and NOTCH1 mutations were found in 30%, 26%, and 14% of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
39 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

for chronic lymphocytic leukemia : prognostic model to predict outcome

  • P Moreton, B Kennedy, G Lucas
  • Leukemia
  • 2013

Similar Papers

Loading similar papers…